MedTrace Logo

SU006668 in Treating Patients With Advanced Solid Tumors

NCT00024063 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2013-12-19

No results posted yet for this study

Summary

RATIONALE: Drugs such as SU006668 may stop the growth of solid tumors by stopping blood flow to the tumor.

PURPOSE: Phase I trial to study the effectiveness of SU006668 in treating patients who have advanced solid tumors.

Conditions

Interventions

DRUG

orantinib

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Jonsson Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Lee S. Rosen, MD · Jonsson Comprehensive Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00024063 on ClinicalTrials.gov